logo
Plus   Neg
Share
Email

Novartis Reports New Phase II Data For IND/GLY/MF

Novartis (NVS) said that new phase II data for new inhaled combination treatment (QVM149) demonstrated significant improvements over current standard-of-care inhaled treatment.

The new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol acetate, glycopyrronium bromide and mometasone furoate, delivered with the dose-confirming Breezhaler inhalation device, was presented at the 2019 annual international congress of the American Thoracic Society.

In two phase II clinical studies, IND/GLY/MF was superior to the comparators,
salmeterol/fluticasone propionate (a standard-of-care treatment) and placebo, separately by demonstrating improvement in lung function in patients with asthma. In one study, IND/GLY/MF also demonstrated improvements versus placebo irrespective of administration time of morning or evening.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A survey has shown that while a majority of Americans want to buy a car that contributes substantially to the U.S. economy amid rising trade tensions, most of the "American-made" cars are actually produced by foreign automakers. According to Cars.com's 2019 American-Made Index, the most 'American-made' vehicle in 2019 is the Jeep Cherokee. Streaming giant Netflix Inc. (NFXL) is set to lose the right to stream "The Office," one of the most popular TV show on the service. NBC Universal announced it is taking back the popular TV show for its own streaming platform, beginning January 2021. "We're sad that NBC has decided to take The... Chinese smartphone maker Xiaomi has announced that its recently launched Mi Band 4 crossed 1 million units sales in just eight days. Xiaomi's Director of Product Management Donovan Sung tweeted this news as he thanked Mi fans for the achievement. "Sharing some great news with our global Mi Fans....
Follow RTT